Payment overview · 2025
General Payments
$440.04
17 reported records · 13 companies
Healthcare provider profile · identity verified
Wade K.C. Licup, MD
Allopathic & Osteopathic Physicians|Family Medicine · VISTA, CA · NPI 1881157998
Verified facts
What the public records show
CMS Open Payments records show Wade K.C. Licup, MD received $440.04 in general payments during 2025 across 17 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $123.91 | 28.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.01 | 17.3% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $35.42 | 8.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.21 | 7.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.79 | 6.8% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $20.94 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.82 | 4.7% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $18.75 | 4.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $17.28 | 3.9% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.68 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.38 | 3.7% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $16.35 | 3.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.50 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $440.04 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $123.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.01 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.01 | 4 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $35.42 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 151 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 131 | 50 |
| Losartan Potassium | Losartan Potassium | 124 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 22 |
| Omeprazole | Omeprazole | 82 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 79 | 29 |
| Gabapentin | Gabapentin | 70 | 22 |
| Lorazepam | Lorazepam | 63 | 11 |
| Metformin Hcl | Metformin Hcl | 63 | 28 |
| Lisinopril | Lisinopril | 60 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 25 |
| Furosemide | Furosemide | 58 | 28 |
| Potassium Chloride | Potassium Chloride | 57 | 14 |
| Simvastatin | Simvastatin | 54 | 20 |
| Carvedilol | Carvedilol | 52 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 21 |
| Tramadol Hcl | Tramadol Hcl | 50 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 11 |
| Trazodone Hcl | Trazodone Hcl | 35 | 18 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Famotidine | Famotidine | 34 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 16 |
| Ibuprofen | Ibuprofen | 27 | 17 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Prednisone | Prednisone | 13 | 12 |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $440.04 · 17 records | Otsuka America Pharmaceutical, Inc. | ACTHAR, APRETUDE, AREXVY, ELIQUIS, EVENITY, GLYCATE, General - Pain Management, Hillrom - Cardiac Ambulatory Monitor, INSPIRE, ImmunoCAP, Kerendia, MOUNJARO, RELTONE 200 MG, RELTONE 400 MG, REXULTI, SHINGRIX, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error